
Management of Generalised Convulsive Status Epilepticus in Adults



Appendix 1: Indications and cautions for stage 3 antiepileptic drugs in the treatment of status epilepticus

Drug	May be preferred:	Cautions to consider:
Levetiracetam	 Already taking Levetiracetam and suspected poor adherence Alternatives contraindicated or previously ineffective Favourable side effect and interaction profile 	 Known allergic reaction Reduce maintenance dose in renal impairment Mood or behavioural disorder (may worsen symptoms)
Phenytoin	 Already taking Phenytoin and suspected poor adherence Alternatives contraindicated or previously ineffective 	 Bradycardia Heart block Porphyria Known allergic reaction Caution in liver disease Administration via enteral tubes can be problematic Therapeutic drug monitoring required
Sodium Valproate	 Already taking Sodium valproate and suspected poor adherence Genetic generalised epilepsy Mood disorder Alternatives contraindicated or previously ineffective 	 Reproductive risks in female and male patients <55 years *see below Pre-existing liver disease or pancreatitis Known metabolic disorder predisposing to hepatotoxicity Known allergic reaction Mitochondrial disease Avoid in patients prescribed carbapenem antibiotics Porphyria

* Sodium Valproate Reproductive Risks: The primary aim in status epilepticus management is termination of seizures and preservation of life. The MHRA have issued <u>advice</u> on use of sodium valproate in female and male patients under 55 years. Decisions regarding ongoing treatment once seizures controlled must be in line with MHRA advice.